Monopar Therapeutics
MNPR
10 hedge funds and large institutions have $314K invested in Monopar Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.02% less ownership
Funds ownership: 0.33% → 0.31% (-0.02%)
23% less funds holding
Funds holding: 13 → 10 (-3)
35% less capital invested
Capital invested by funds: $484K → $314K (-$170K)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.1K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$2.22K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.44K |
| 4 |
PWS
Paragon Wealth Strategies
Jacksonville,
Florida
|
+$114 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$26.8K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$9K |
| 3 |
BlackRock
New York
|
-$5K |
| 4 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$1.61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $152K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $59K | – | – | – |
|
|
3
Northern Trust
Chicago,
Illinois
| $55K | +$2.22K | +234 | +3% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $16K | +$20.1K | +2,117 | New |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| $13K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $8K | -$26.8K | -2,832 | -72% |
|
7
Morgan Stanley
New York
| $6K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $5K | +$1.44K | +152 | +32% |
|
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$9K | -823 | Closed |
|
|
10
BlackRock
New York
| – | -$5K | -465 | Closed |
|
|
APA
11
American Portfolios Advisors
Holbrook,
New York
| – | -$1.61K | -140 | Closed |
|
|
PWS
12
Paragon Wealth Strategies
Jacksonville,
Florida
| – | +$114 | +12 | New |
|
MNPR Hedge Fund Activity: Q3 2022 in Review
10 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2022, worth a combined $314K — down 35% from $484K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MNPR and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $20.1K. The largest seller was UBS Group, cutting an estimated $26.8K.
- 10 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2022, down from 13 in Q2 2022.
- Funds reported $314K of Monopar Therapeutics stock for Q3 2022, down 35% quarter-over-quarter.
- 2 funds opened new Monopar Therapeutics positions in Q3 2022 and 5 closed out, a net change of -3 holders.
- The largest Monopar Therapeutics buyer in Q3 2022 was Susquehanna International Group, an estimated $20.1K added.
- The largest Monopar Therapeutics seller in Q3 2022 was UBS Group, an estimated $26.8K sold.
Based on aggregated 13F filings for Q3 2022.